daejeon,april13,2017

legochembioscienses(“lcb”)isabiopharmaceuticalcompanyfocusingontheresearch&developmentofadcs,basedindaejeonsouthkorea,announcedtodaythatthecompanywasawardedu.s.patentno.14517616,entitled“antibodyactiveagentconjugatesandmethodsofuse”.

thepatentillustratesthecompany’sconjuall^{tm technology,legochem’sproprietaryadcplatformwhichenablesthedesignofhomogeneousplasmastableadcswiththepotentialforimprovedpayloaddeliverytocancercells.  thispatentprovideslcbcomprehensivecoverageintheunitedstatesforitsadcplatformtechnology.} 

dr.yeongsoo oh,seniorvicepresident&chieftechnologyofficeroflcbsaid,“thispatentfurtherstrengthenslcb’scompetitiveadvantageinthefieldofresearchanddevelopmentofnextgenerationadcs.theuseofourtechnologywilladdress significantunmetneedsofcurrentadctechnologies.

lcbhasbeensuccessfullydevelopingglobalpartnershipsthroughthepotentialofitsproprietaryadcplatformtechnology.in2015,lcboutlicensed anantiher2adcmoleculetofosunpharmaandinjanuary2017,signedaresearchlicensingdealwithtakeda, toevaluatenextgenerationadccandidates.

aboutlegochembiosciences

legochembiosciencesisabiopharmaceuticalcompanyfocusingonthedevelopmentofnextgenerationnoveltherapeuticsutilizingitsproprietarymedicinaldrugdiscoverytechnologylegochemistry™&adcplatformtechnologyconjuall™.  sinceitsfoundationin2006,lcbhasfocusedontheresearchanddevelopmentofadc(antibodydrugconjugates),antibiotics,anticoagulantsandanticancertherapeuticsbasedonitsproprietaryplatformtechnologies.

aboutconjuall^tm

conjuall^{tm isanextgenerationadcplatformtechnologyutilizingnovellinkerchemistrycombinedwithsitespecificenzymaticconjugation.ourplatformprovidessolutionsforsitespecificconjugation,linkerstabilityandefficientpayloadreleasewhicharethreemajorunmetneedsinadcdevelopment.}

forlegochembiosciences

bdenquiries

jeiwookchae,chiefbusinessdevelopmentofficer

tel:+82428610688

email:bd@legochembio.com

media&investorsenquiries

wooshikkim,manager

tel:+827048113260

email: ir@legochembio.com